➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Mallinckrodt
AstraZeneca
Express Scripts
Colorcon
McKesson
Moodys

Last Updated: August 11, 2020

DrugPatentWatch Database Preview

IMODIUM MULTI-SYMPTOM RELIEF Drug Profile

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

When do Imodium Multi-symptom Relief patents expire, and when can generic versions of Imodium Multi-symptom Relief launch?

Imodium Multi-symptom Relief is a drug marketed by J And J Consumer Inc and is included in two NDAs.

The generic ingredient in IMODIUM MULTI-SYMPTOM RELIEF is loperamide hydrochloride; simethicone. There are eleven drug master file entries for this compound. Eighteen suppliers are listed for this compound. Additional details are available on the loperamide hydrochloride; simethicone profile page.

Summary for IMODIUM MULTI-SYMPTOM RELIEF
Drug patent expirations by year for IMODIUM MULTI-SYMPTOM RELIEF
Recent Clinical Trials for IMODIUM MULTI-SYMPTOM RELIEF

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Naia PharmaceuticalsPhase 1/Phase 2
McNeil ABPhase 1
AllerganPhase 2

See all IMODIUM MULTI-SYMPTOM RELIEF clinical trials

Paragraph IV (Patent) Challenges for IMODIUM MULTI-SYMPTOM RELIEF
Tradename Dosage Ingredient NDA Submissiondate
IMODIUM MULTI-SYMPTOM RELIEF TABLET;ORAL loperamide hydrochloride; simethicone 021140 2004-12-29
IMODIUM MULTI-SYMPTOM RELIEF TABLET, CHEWABLE;ORAL loperamide hydrochloride; simethicone 020606

US Patents and Regulatory Information for IMODIUM MULTI-SYMPTOM RELIEF

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
J And J Consumer Inc IMODIUM MULTI-SYMPTOM RELIEF loperamide hydrochloride; simethicone TABLET, CHEWABLE;ORAL 020606-001 Jun 26, 1996 DISCN Yes No   Start Trial   Start Trial   Start Trial
J And J Consumer Inc IMODIUM MULTI-SYMPTOM RELIEF loperamide hydrochloride; simethicone TABLET;ORAL 021140-001 Nov 30, 2000 OTC Yes Yes   Start Trial   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for IMODIUM MULTI-SYMPTOM RELIEF

Supplementary Protection Certificates for IMODIUM MULTI-SYMPTOM RELIEF

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
0428296 99C0029 Belgium   Start Trial PRODUCT NAME: LOPERAMIDUM HYDROCHOLORIDUM SEMITHICONUM; NATL. REGISTRATION NO/DATE: 2 IS 145 F3 19990201; FIRST REGISTRATION: GB PL 00242/0314 19970923
0428296 SPC/GB98/013 United Kingdom   Start Trial PRODUCT NAME: LOPERAMIDE HYDROCHLORIDE AND SIMETHICONE; REGISTERED: UK 00242/0314 19970923
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Dow
Mallinckrodt
McKinsey
Medtronic
AstraZeneca
McKesson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.